Robert Uger, Chief Scientific Officer at Trillium Therapeutics Inc. (TRIL), sold 3,646 shares at $8.27 ($30K) on 2021-06-07, disclosed to the SEC on 2021-06-09.
Scheduled sale ($30k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRIL | SELL | 2021-04-09 | $39K | — | Filing → |
| TRIL | SELL | 2021-03-15 | $35K | — | Filing → |
| TRIL | SELL | 2021-03-10 | $37K | — | Filing → |